Chronic inflammation contributes to cancer development via multiple mechanisms and it is a key factor for sustaining autoimmune disorders. One potential mechanism is that chronic inflammation can generate an immunosuppressive microenvironment that allows advantages for tumor or disease formation and progression. The tumor and autoimmune disease microenvironment is characterized, for example, by accumulation of pro-inflammatory mediators such as cytokines, chemokines and prostaglandins, deregulated immune cells, infiltration of immune suppressor cells and activation of immune checkpoint pathway. Moreover, this variety of cells and soluble factors are capable of favor, for example, growth of tumor cells, recruitment of other immunosuppressive players that, in turns, inactivate the effector function of several therapy including adaptive and innate immune cells.
In this issue, we will address several ongoing challenges in the identification, characterization, interaction, as well as role and impact of the different immunosuppressive elements present inside of the tumor microenvironment as well in chronic disease microenvironment like autoimmune disorders.
Increasing evidence, in fact, demonstrates that these elements play a crucial role in the creation of a particular microenvironment which, following the immunological pressure, facilitates the activation of resistance mechanisms capable of reducing or even inactivating the effectiveness of conventional treatments and more advanced strategies such as monoclonal therapies or adoptive cellular therapies.
The final goal will be to establish strategies to better target these elements and reduce or modulate the immunosuppression making treatments more effective reducing, in meantime, possible toxicity. Particular attention will be dedicated to the intracellular interaction, microenvironment (low pH, low oxygen, ect...), 3D modeling and molecular signatures.
In this issue, we are looking to receive Original Research, Reviews, Mini Reviews, Systematic Reviews, Methods, Data Reports, Perspectives and Opinion articles related to the following sub-topics:
• Strategies to better characterize and target the immune suppressive elements of the tumor microenvironment and autoimmune disease microenvironment.
• Immunosuppressive mechanisms mediated by immune suppressive elements like Tregs, MDSCs, TAMs and CAFs in terms of signaling, metabolism, 3D interaction and clinical impact.
• Definitions of the mechanism to the resistance to conventional treatment as well as to immunotherapeutic approaches including but not limited to adoptive cell therapies.
Chronic inflammation contributes to cancer development via multiple mechanisms and it is a key factor for sustaining autoimmune disorders. One potential mechanism is that chronic inflammation can generate an immunosuppressive microenvironment that allows advantages for tumor or disease formation and progression. The tumor and autoimmune disease microenvironment is characterized, for example, by accumulation of pro-inflammatory mediators such as cytokines, chemokines and prostaglandins, deregulated immune cells, infiltration of immune suppressor cells and activation of immune checkpoint pathway. Moreover, this variety of cells and soluble factors are capable of favor, for example, growth of tumor cells, recruitment of other immunosuppressive players that, in turns, inactivate the effector function of several therapy including adaptive and innate immune cells.
In this issue, we will address several ongoing challenges in the identification, characterization, interaction, as well as role and impact of the different immunosuppressive elements present inside of the tumor microenvironment as well in chronic disease microenvironment like autoimmune disorders.
Increasing evidence, in fact, demonstrates that these elements play a crucial role in the creation of a particular microenvironment which, following the immunological pressure, facilitates the activation of resistance mechanisms capable of reducing or even inactivating the effectiveness of conventional treatments and more advanced strategies such as monoclonal therapies or adoptive cellular therapies.
The final goal will be to establish strategies to better target these elements and reduce or modulate the immunosuppression making treatments more effective reducing, in meantime, possible toxicity. Particular attention will be dedicated to the intracellular interaction, microenvironment (low pH, low oxygen, ect...), 3D modeling and molecular signatures.
In this issue, we are looking to receive Original Research, Reviews, Mini Reviews, Systematic Reviews, Methods, Data Reports, Perspectives and Opinion articles related to the following sub-topics:
• Strategies to better characterize and target the immune suppressive elements of the tumor microenvironment and autoimmune disease microenvironment.
• Immunosuppressive mechanisms mediated by immune suppressive elements like Tregs, MDSCs, TAMs and CAFs in terms of signaling, metabolism, 3D interaction and clinical impact.
• Definitions of the mechanism to the resistance to conventional treatment as well as to immunotherapeutic approaches including but not limited to adoptive cell therapies.